Cargando…

Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic disease characterised by aberrant fibroblast/myofibroblast accumulation and excessive collagen matrix deposition in the alveolar areas of lungs. As the first approved IPF medication, pirfenidone (PFD) significantly decelerates...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Hsiao-Yen, Vander Heiden, Jason A., Uttarwar, Salil, Xi, Ying, N'Diaye, Elsa-Noah, LaCanna, Ryan, Caplazi, Patrick, Gierke, Sarah, Moffat, John, Wolters, Paul J., Ding, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133585/ https://www.ncbi.nlm.nih.gov/pubmed/36585256 http://dx.doi.org/10.1183/13993003.00604-2022

Ejemplares similares

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020)

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
por: Xi, Yue, et al.
Publicado: (2021)

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
por: Jin, Jin, et al.
Publicado: (2019)

Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone
por: Andersen, Stine, et al.
Publicado: (2019)

The ubiquitin-related protein PLIC-1 regulates heterotrimeric G protein function through association with Gβγ
por: N'Diaye, Elsa-Noah, et al.
Publicado: (2003)

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
por: Mediavilla-Varela, Melanie, et al.
Publicado: (2016)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis
por: Bracco Gartner, Thomas C. L., et al.
Publicado: (2022)

BMP1 is not required for lung fibrosis in mice
por: Ma, Hsiao-Yen, et al.
Publicado: (2022)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
por: Fernández Pérez, Evans R., et al.
Publicado: (2021)

LOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung
por: Ma, Hsiao-Yen, et al.
Publicado: (2023)

Gene regulation and deregulation by MAL/MRTF coactivators
por: Posern, G
Publicado: (2009)

MRTF: Basic Biology and Role in Kidney Disease
por: Miranda, Maria Zena, et al.
Publicado: (2021)

Correction to: Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

MRTF-A can activate Nrf2 to increase the resistance to doxorubicin
por: Xu, Yao, et al.
Publicado: (2016)

The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
por: Ferrara, Francesco, et al.
Publicado: (2020)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G(1) Cell Cycle Arrest
por: Ishii, Kenichiro, et al.
Publicado: (2019)

The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-β and MMP-1
por: Tao, Yijin, et al.
Publicado: (2020)

Pulmonary Silicosis Alters MicroRNA Expression in Rat Lung and miR-411-3p Exerts Anti-fibrotic Effects by Inhibiting MRTF-A/SRF Signaling
por: Gao, Xuemin, et al.
Publicado: (2020)

Profibrotic epithelial phenotype: a central role for MRTF and TAZ
por: Bialik, Janne Folke, et al.
Publicado: (2019)

MRTF specifies a muscle-like contractile module in Porifera
por: Colgren, J., et al.
Publicado: (2022)

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
por: Feng, Haoshen, et al.
Publicado: (2020)

MRTF/SRF dependent transcriptional regulation of TAZ in breast cancer cells
por: Liu, Chen-Ying, et al.
Publicado: (2016)

Regulation of MRTF-A by JMY via a nucleation-independent mechanism
por: Kluge, Franziska, et al.
Publicado: (2018)

Migration arrest of chemoresistant leukemia cells mediated by MRTF-SRF pathway
por: Morimatsu, Maho, et al.
Publicado: (2020)

Regulation of Dendritic Synaptic Morphology and Transcription by the SRF Cofactor MKL/MRTF
por: Tabuchi, Akiko, et al.
Publicado: (2021)

Pirfenidone-induced Eosinophilic Pleurisy
por: Hase, Isano, et al.
Publicado: (2017)

Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
por: Jiang, Zhaosheng, et al.
Publicado: (2022)

Synthetic liver fibrotic niche extracts achieve in vitro hepatoblasts phenotype enhancement and expansion
por: Zhang, Yuying, et al.
Publicado: (2021)

MICU1-dependent mitochondrial calcium uptake regulates lung alveolar type 2 cell plasticity and lung regeneration
por: Ali, Mir, et al.
Publicado: (2022)

MRTF transcription and Ezrin-dependent plasma membrane blebbing are required for entotic invasion
por: Hinojosa, Laura Soto, et al.
Publicado: (2017)

Phosphorylation acts positively and negatively to regulate MRTF-A subcellular localisation and activity
por: Panayiotou, Richard, et al.
Publicado: (2016)

Actomyosin and the MRTF-SRF pathway downregulate FGFR1 in mesenchymal stromal cells
por: Zonderland, Jip, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l2nlvlb7opm84e4vln01jqlqem